Bank of New York Mellon’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.1M | Buy |
84,880
+9,951
| +13% | +$129K | ﹤0.01% | 3066 |
|
|
2025
Q1 | $793K | Sell |
74,929
-3,251
| -4% | -$34.4K | ﹤0.01% | 3172 |
|
|
2024
Q4 | $1.33M | Sell |
78,180
-22,024
| -22% | -$374K | ﹤0.01% | 2960 |
|
|
2024
Q3 | $2.33M | Sell |
100,204
-18,977
| -16% | -$440K | ﹤0.01% | 2675 |
|
|
2024
Q2 | $2.9M | Buy |
119,181
+3,578
| +3% | +$87.1K | ﹤0.01% | 2591 |
|
|
2024
Q1 | $3.9M | Sell |
115,603
-17,316
| -13% | -$585K | ﹤0.01% | 2436 |
|
|
2023
Q4 | $4.19M | Buy |
132,919
+38,492
| +41% | +$1.21M | ﹤0.01% | 2460 |
|
|
2023
Q3 | $2.41M | Buy |
94,427
+3,587
| +4% | +$91.6K | ﹤0.01% | 2701 |
|
|
2023
Q2 | $2.61M | Buy |
90,840
+15,499
| +21% | +$445K | ﹤0.01% | 2682 |
|
|
2023
Q1 | $1.81M | Sell |
75,341
-1,241
| -2% | -$29.7K | ﹤0.01% | 2858 |
|
|
2022
Q4 | $1.3M | Buy |
76,582
+986
| +1% | +$16.7K | ﹤0.01% | 3068 |
|
|
2022
Q3 | $1.12M | Buy |
75,596
+6,711
| +10% | +$99.5K | ﹤0.01% | 3148 |
|
|
2022
Q2 | $1.08M | Sell |
68,885
-8,885
| -11% | -$140K | ﹤0.01% | 3177 |
|
|
2022
Q1 | $2.1M | Sell |
77,770
-268
| -0.3% | -$7.23K | ﹤0.01% | 2906 |
|
|
2021
Q4 | $2.89M | Buy |
78,038
+1,261
| +2% | +$46.7K | ﹤0.01% | 2764 |
|
|
2021
Q3 | $3.67M | Buy |
76,777
+6,008
| +8% | +$287K | ﹤0.01% | 2642 |
|
|
2021
Q2 | $2.4M | Sell |
70,769
-3,016
| -4% | -$102K | ﹤0.01% | 2871 |
|
|
2021
Q1 | $3.05M | Sell |
73,785
-7,428
| -9% | -$307K | ﹤0.01% | 2672 |
|
|
2020
Q4 | $3.52M | Buy |
81,213
+18,424
| +29% | +$799K | ﹤0.01% | 2527 |
|
|
2020
Q3 | $2.69M | Buy |
62,789
+9,897
| +19% | +$425K | ﹤0.01% | 2508 |
|
|
2020
Q2 | $2.47M | Buy |
+52,892
| New | +$2.47M | ﹤0.01% | 2551 |
|